Davenport & Co’s Nuvation Bio NUVB Stock Holding History

Davenport & Co’s Portfolio NUVB Stock Details NUVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-16,000	Closed	-$149K	–	1040
2021 Q2	$149K	Buy	+16,000	New	+$182K	﹤0.01%	916

Other funds holding NUVB

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Davenport & Co's NUVB Position: Q3 2021 in Review

Davenport & Co sold out of Nuvation Bio (NUVB) in Q3 2021, closing a stake of 16,000 shares — an estimated $149K sold.

Davenport & Co first reported a position in NUVB in Q2 2021 and held it in 1 quarter. The position peaked at $149K in Q2 2021. 98 funds tracked by Wall St. Rank hold NUVB as of Q3 2021.

Davenport & Co reported no remaining Nuvation Bio position as of Q3 2021 after selling out during the quarter.
Davenport & Co sold 16,000 Nuvation Bio shares in Q3 2021, an estimated $149K.
Davenport & Co first reported a position in Nuvation Bio in Q2 2021 and held it in 1 quarter.
Davenport & Co's Nuvation Bio position peaked at $149K in Q2 2021.
98 funds tracked by Wall St. Rank held Nuvation Bio as of Q3 2021.

Based on Davenport & Co's 13F filing for Q3 2021, filed 14 Oct 2021.